In The Know: Analyst answers — Are changes coming for RCC treatment?

What does the future hold for renal cell carcinoma (RCC) therapies? We sat down with senior KOL Insights analyst Sarah Harris to discuss her research into recent developments and what new therapies have potential to shake up the market over the next three-to-five years. Here she shares some key findings from in-depth interviews with key opinion leaders (KOLs) on the topic.

FirstWord: What was the main objective for this research?

Sarah Harris: This research seeks to understand what the key trends are in the evolving treatment of RCC. What will be the key players and developments that will change the face of RCC treatment in the next five years? What are the most important opportunities and threats for companies investing or seeking to invest in this area?

FW: Based on the research, what is the general sentiment from KOLs on the progression of the RCC treatment landscape?

SH: It’s an exciting time for the evolving RCC treatment paradigm and the KOLs are most enthusiastic about the host of IO-based combination therapies that are progressing through development.

FW: What is one of the most notable changes over the last 12 months in RCC treatment your research has found?

SH: In April 2018, the FDA approved Opdivo (nivolumab; Bristol-Myers Squibb) plus Yervoy (ipilimumab; Bristol-Myers Squibb) for the treatment of patients with intermediate or poor risk, previously untreated advanced RCC. This represents a major development in the treatment of RCC as it is the first IO combination regimen to be approved

FW: What was one of the most insightful KOL interview quotes? What did it teach us?

SH: “It’s been an incredible time, from not having anything but cytokines pre-2005, to VEGF TKIs, and now IO in combination. The landscape is moving towards being IO-oriented. My initial expectation was that it was going to be a pure IO approach, but I think I am being proven wrong by the initial data from combination trials.” [US Key Opinion Leader]

This gives insight into just how rapidly the landscape is evolving and that (IO-based) combinations really will be the key to front-line treatment in the future.

To learn more about this recent research, click here.




To read more Sponsored Story articles, click here.

Reference Articles